What is a stock summary page? Click here for an overview.
Business Description
Innovent Biologics Inc
ISIN : KYG4818G1010
Share Class Description:
HKSE:01801: Ordinary SharesCompare
Compare
Traded in other countries / regions
01801.Hong KongIVBXF.USA6IB.Germany Index Membership
Hong Kong Stock ConnectiShares MSCI ACWI Ex US Index FundHang Seng China Enterprises Index IPO Date
2018-10-31Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.79 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 6.95 | |||||
| Interest Coverage | 3.76 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 5.26 | |||||
| Beneish M-Score | -2.13 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.8 | |||||
| 3-Year EPS without NRI Growth Rate | 61 | |||||
| 3-Year FCF Growth Rate | 56.2 | |||||
| 3-Year Book Growth Rate | -0.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 24.95 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.9 | |||||
| 9-Day RSI | 51.19 | |||||
| 14-Day RSI | 54.02 | |||||
| 3-1 Month Momentum % | 23.07 | |||||
| 6-1 Month Momentum % | 24.06 | |||||
| 12-1 Month Momentum % | 15.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.35 | |||||
| Quick Ratio | 2.16 | |||||
| Cash Ratio | 1.8 | |||||
| Days Inventory | 201.47 | |||||
| Days Sales Outstanding | 46.26 | |||||
| Days Payable | 77.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | 0.55 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.97 | |||||
| Operating Margin % | 2.7 | |||||
| Net Margin % | -1.04 | |||||
| EBITDA Margin % | 4.31 | |||||
| FCF Margin % | -4.51 | |||||
| ROE % | -0.76 | |||||
| ROA % | -0.46 | |||||
| ROIC % | 2.47 | |||||
| 3-Year ROIIC % | 46.33 | |||||
| ROC (Joel Greenblatt) % | -0.27 | |||||
| ROCE % | -0.08 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 220.78 | |||||
| PS Ratio | 8.23 | |||||
| PB Ratio | 5.96 | |||||
| Price-to-Tangible-Book | 6.82 | |||||
| Price-to-Operating-Cash-Flow | 60.71 | |||||
| EV-to-EBIT | -5137.86 | |||||
| EV-to-Forward-EBIT | 263.03 | |||||
| EV-to-EBITDA | 175.51 | |||||
| EV-to-Forward-EBITDA | 76.79 | |||||
| EV-to-Revenue | 7.56 | |||||
| EV-to-Forward-Revenue | 6.3 | |||||
| EV-to-FCF | -167.66 | |||||
| Price-to-GF-Value | 0.81 | |||||
| Price-to-Net-Current-Asset-Value | 43.59 | |||||
| Earnings Yield (Greenblatt) % | -0.02 | |||||
| FCF Yield % | -0.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Innovent Biologics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 10,094.549 | ||
| EPS (TTM) (HK$) | -0.066 | ||
| Beta | 0.74 | ||
| 3-Year Sharpe Ratio | 0.65 | ||
| 3-Year Sortino Ratio | 1.11 | ||
| Volatility % | 49.56 | ||
| 14-Day RSI | 54.02 | ||
| 14-Day ATR (HK$) | 3.019648 | ||
| 20-Day SMA (HK$) | 51.63 | ||
| 12-1 Month Momentum % | 15.95 | ||
| 52-Week Range (HK$) | 28.65 - 56.1 | ||
| Shares Outstanding (Mil) | 1,638.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Innovent Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Innovent Biologics Inc Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Innovent Biologics Inc Frequently Asked Questions
What is Innovent Biologics Inc(HKSE:01801)'s stock price today?
The current price of HKSE:01801 is HK$51.00. The 52 week high of HKSE:01801 is HK$56.10 and 52 week low is HK$28.65.
When is next earnings date of Innovent Biologics Inc(HKSE:01801)?
The next earnings date of Innovent Biologics Inc(HKSE:01801) is 2025-08-28 Est..
Does Innovent Biologics Inc(HKSE:01801) pay dividends? If so, how much?
Innovent Biologics Inc(HKSE:01801) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers